Amgen's $8.1 Billion Cash Flow Meets Axsome's Growth Bet
Amgen produced $8.1 billion of free cash flow in 2025 with a 21% net margin. Axsome Therapeutics is still unprofitable. Two very different healthcare bets, priced accordingly.
Amgen generated $8.1 billion in free cash flow in 2025 on a 21% net margin, while Axsome Therapeutics continues to scale revenue without reaching profitability, framing a choice between cash returns and growth for healthcare investors in 2026.
Two healthcare names, two entirely different propositions. Amgen (NASDAQ: AMGN) converted its scale into $8.1 billion of free cash flow in 2025 and held a 21% net margin — meaning roughly a fifth of every revenue dollar reached the bottom line. Axsome Therapeutics (NASDAQ: AXSM) is doing something else altogether: growing its commercial base quickly while still running at a loss.
The comparison, laid out by Motley Fool, is less a question of which company is better run than of what an investor is being paid to own. One stock is a cash-return instrument with patent risk attached. The other is an option on execution.
What $8.1 billion of free cash flow actually buys
Free cash flow is the money left after a company pays its operating bills and funds its capital spending. It is the pool that dividends, buybacks, debt paydown and acquisitions come out of. At $8.1 billion for 2025, Amgen has one of the larger such pools in biotech, and that is the entire investment case in a sentence: the company does not need capital markets to be friendly in order to keep doing what it does.
The 21% net margin matters for a different reason. Large-cap pharma margins are a function of pricing power and the mix of drugs still under patent protection. A margin at that level tells you the portfolio is not yet being hollowed out by generic and biosimilar competition — though for any company of Amgen's vintage, that is a running battle rather than a settled question. Investors buying Amgen are, in effect, buying the durability of that margin, and the pipeline and business development spending meant to defend it.
Shares last closed at $432.42, down 1.05% on the session, inside a day range of $430.72 to $437.89 and below the prior close of $436.99, according to licensed market data as of Fri, 28 Aug 2026 20:00 GMT. That was a softer session for the market generally: the S&P 500 tracker closed at $769.35, off 0.23%, and the Nasdaq 100 tracker at $716.43, down 0.65%.
Axsome is spending to build a franchise, not to report a profit
Axsome sits at the stage where revenue is climbing but the income statement has not caught up. That is not automatically a flaw. Commercial-stage neuroscience companies carry heavy sales-force and marketing costs precisely because prescriber adoption is won field by field, and those costs land ahead of the revenue they generate. Profitability arrives — if it arrives — when the installed prescriber base grows faster than the cost of servicing it.
The risk is that the arithmetic of "scaling rapidly but still unprofitable" cuts both ways. A company in that position is dependent on continued top-line acceleration to justify its valuation, and on its balance sheet to bridge the gap until operating leverage shows up. Any stumble in launch trajectory, reimbursement, or a pipeline readout hits harder than it would at a company already generating cash.
Axsome closed at $199.02, down 3.51%, having traded between $199.00 and $205.70 on the day against a prior close of $206.27. It finished at the bottom of its range — the sort of close that tells you sellers had the last word, and a reminder that unprofitable growth names tend to move more than the index on days when the tape is heavy.
The valuation question sits on opposite sides of the same coin
With Amgen, an investor knows roughly what the cash flow is and is arguing about how long it lasts. With Axsome, the cash flow is the thing being forecast, and the argument is about how large it eventually gets and how much dilution or debt it takes to get there. Those are not comparable risks dressed differently. They are different risks.
A few practical distinctions worth holding onto:
- Downside behavior. A company producing billions in free cash flow has levers — cut buybacks, slow deals — that a pre-profit company does not.
- What a good year looks like. For Amgen, a good 2026 is margin defense and pipeline progress. For Axsome, it is revenue growth steep enough to visibly narrow losses.
- Who each suits. Income-oriented and defensive portfolios lean toward the cash generator. Growth allocations, sized small enough to survive being wrong, are where the pre-profit name fits.
- Correlation to the broad market. Large-cap pharma often trades on drug-specific news; smaller, unprofitable biotech is more sensitive to interest rates and risk appetite, because its value is weighted toward distant cash flows.
Catalysts that will settle the argument in 2026
Neither stock is likely to be re-rated on sentiment alone. For Amgen, the watch items are whether that 21% net margin holds as the year progresses, how much of the $8.1 billion cash engine gets recycled into returns versus acquisitions, and any change in the competitive position of its larger products. Free cash flow of that size is a shock absorber, but it is not a growth story by itself — investors have to see it deployed into something.
For Axsome, the single most consequential number in each quarterly report is the gap between revenue growth and operating expense growth. Narrowing that gap is what converts a growth story into a business. Widening it, even with strong revenue, is the scenario that forces harder conversations about financing.
The honest answer to "which is the better buy" is that they answer different questions. If the requirement is capital that compounds without needing a catalyst, the $8.1 billion figure and the 21% margin do most of the talking. If the requirement is upside large enough to matter to a whole portfolio, the unprofitable name is where that lives — along with the possibility of a permanent loss that the cash generator largely does not carry.
How the tape framed the choice heading into September
The final session before the month turned was mildly negative across the board — the Dow tracker closed at $535.06, essentially flat at -0.03%, with the broader indexes down modestly. Against that, Amgen's 1.05% decline reads as ordinary drift, while Axsome's 3.51% fall was a multiple of the market's move. That relationship is the clearest live illustration of the tradeoff: the same day treats the two stocks very differently, and it will keep doing so.
Investors weighing the pair should decide which of those two experiences they are equipped to sit through, rather than which company has the more appealing story. The story is usually the easy part.
Key facts
- AMGN last close: $432.42, -1.05% (as of Fri, 28 Aug 2026 20:00 GMT)
- AXSM last close: $199.02, -3.51% (as of Fri, 28 Aug 2026 20:00 GMT)
- Amgen 2025 free cash flow: $8.1 billion
- Amgen net margin: 21%
Frequently asked questions
How much free cash flow did Amgen generate in 2025?
Amgen generated $8.1 billion in free cash flow in 2025. Free cash flow is the cash left after operating expenses and capital spending, and it is the pool a company draws on to fund dividends, share buybacks, debt repayment and acquisitions. Amgen also reported a 21% net margin over the same period.
Is Axsome Therapeutics profitable?
No. Axsome Therapeutics is scaling its revenue rapidly but remains unprofitable. Commercial-stage neuroscience companies typically carry heavy sales and marketing costs that arrive ahead of the revenue they generate, so profitability depends on revenue growing faster than operating expenses over time.
What did the two stocks last close at?
As of the last trade on Fri, 28 Aug 2026 at 20:00 GMT, Amgen closed at $432.42, down 1.05% from a prior close of $436.99. Axsome Therapeutics closed at $199.02, down 3.51% from $206.27, finishing near the low of its $199.00 to $205.70 day range.
What does a 21% net margin tell investors about Amgen?
A 21% net margin means roughly a fifth of Amgen's revenue reached the bottom line. For a large-cap drugmaker, a margin at that level suggests pricing power and a portfolio still substantially protected from generic and biosimilar competition. Whether that margin holds is the central question for the investment case.
Why did Axsome fall more than Amgen on the same day?
Smaller, unprofitable biotech names are typically more sensitive to risk appetite and interest rates because their value sits in distant, uncertain cash flows. On the last session before month-end, broad market trackers slipped modestly while Axsome fell 3.51% and Amgen fell 1.05%, a routine illustration of that difference in volatility.
Which stock suits which type of investor?
Amgen's large free cash flow and established margin fit income-oriented or defensive portfolios that want returns without depending on a specific catalyst. Axsome fits growth allocations sized small enough to absorb being wrong, since its outcome depends on revenue growth outpacing costs before financing becomes a constraint.
Sources
Photo: cottonbro studio · Pexels Licence — source
